Osteoporosis Canada refines fracture prevention for adults 50 and older
Canada’s updated osteoporosis guideline places fracture risk at the center of care rather than bone density alone. The message is blunt: skeletal fragility is common, fractures are costly, and older adults cannot be managed well with a one-size-fits-all approach. More than 2 million people in Canada live with osteoporosis, and hip fracture rates remain high enough to keep this condition firmly in the realm of everyday clinical medicine, not rare disease.
Fractures are not benign events. They bring excess mortality, persistent disability, loss of independence and a measurable decline in quality of life. In older adults, the biology is familiar but unforgiving: advancing age weakens bone, fall risk rises, and the combination turns a low-energy event into a major injury.
Risk assessment now drives treatment decisions
The guideline update keeps the clinical threshold anchored to validated tools and known fracture history. A diagnosis of osteoporosis can be made in adults aged 50 years and older who have sustained a low-trauma hip, vertebral, humerus or pelvic fracture after age 40, or who have an absolute 10-year fracture risk of 20% or more using FRAX or CAROC. Bone mineral density still matters, but it is no longer the only signal that counts. A T-score at or below −2.5 remains a defining marker, yet age, sex and the broader clinical picture shape the real-world decision.
One sentence captures the clinical shift: fracture history can diagnose osteoporosis even when bone density has not yet crossed the traditional threshold.
That matters at the bedside because many fractures occur before a patient ever receives a formal osteoporosis label. Vertebral injuries, in particular, may hide in plain sight until a patient presents with height loss, back pain, or an unexpected decline in function. The guideline advises considering lateral spine imaging to identify occult vertebral fractures, since finding one can change both the choice and the duration of therapy.
Men remain under-recognized and undertreated
The update gives clear weight to a long-standing gap in care: men are less likely to be evaluated and treated, even though their outcomes after fracture are often worse. Osteoporosis is still commonly framed as a postmenopausal condition, but that framing leaves too many older men outside the diagnostic pathway. The guideline therefore extends its practical focus to males aged 50 years and older, with recommendations tailored when evidence is thinner in men than in women.
That evidence imbalance is not a minor technical issue. It shapes how confidently clinicians can apply pharmacologic data, and it explains why the document sometimes assigns different strengths of recommendation by sex. Primary care clinicians are being asked to do more than order a scan; they are expected to assess risk, interpret evidence conservatively when the male data are sparse, and act before the first major fracture.
Exercise, nutrition and medications now sit in one prevention plan
The guideline organizes care into exercise, nutrition, fracture risk assessment, treatment initiation, pharmacologic interventions, duration and sequence of therapy, and monitoring. The logic is straightforward. Bone strength is influenced by loading, substrate and medication response; fracture risk is also shaped by muscle function, balance and overall frailty. Exercise and nutrition therefore remain core elements of prevention, not optional add-ons.
Medication decisions should follow the patient’s fracture risk profile and clinical context. Antiresorptive therapy includes bisphosphonates such as alendronate, risedronate and zoledronic acid, as well as denosumab, raloxifene and menopausal hormone therapy. For females younger than 60 years or within 10 years after menopause who also prioritize relief of substantial menopausal symptoms, menopausal hormone therapy is presented as a suggested alternative. Raloxifene is suggested for females who cannot take, do not tolerate, or choose not to use other suggested therapies.
The pharmacology here tracks with the disease biology. Bone loss reflects an imbalance between resorption and formation, and antiresorptive agents blunt the resorptive arm of that equation. In patients at high risk, the goal is not abstract improvement in a lab value; it is preventing the next low-trauma fracture that would otherwise change mobility, autonomy and prognosis.
Secondary causes and fall risk still demand a wider lens
Primary osteoporosis is the focus of the update, but the document makes clear that secondary causes must not be missed. Conditions such as hyperparathyroidism, multiple myeloma, newly diagnosed rheumatoid arthritis and other inflammatory disorders requiring high-dose glucocorticoids fall outside the main treatment scope and should trigger evaluation for secondary osteoporosis, with specialist co-management when appropriate.
Falls remain a major driver of fractures in older adults. Because detailed fall-prevention guidance was beyond the scope of this update, the document directs clinicians to the Canadian Task Force on Preventive Health Care recommendations on falls prevention. The clinical takeaway is practical: bone health cannot be separated from balance, gait, vision, medications and environmental hazards. Even the best pharmacotherapy cannot fully compensate for an untreated fall hazard.
Sequencing, monitoring and duration are part of the treatment decision
The guideline also addresses duration and sequence of therapy, an area where many clinicians need help because treatment response is not uniform across agents or across risk groups. Monitoring is built into the recommendation set, and reassessment should occur earlier if a patient develops a secondary cause, sustains a new fracture, or acquires another risk factor for rapid bone loss. In other words, treatment is not a one-time prescription. It is a longitudinal process that depends on changing risk.
This is especially relevant when vertebral fractures have gone unrecognized. Detecting them can influence not only whether treatment begins, but also how long it should continue and whether a different sequence of therapy is warranted. The presence of a prior fragility fracture often marks a patient whose skeletal reserve has already failed once; repeating the same approach without revisiting risk leaves little margin for error.
A guideline built for primary care use
The update was developed with the GRADE framework and AGREE II standards, with primary care physicians and patient partners involved throughout the process. Competing interests were managed using principles from the Guideline International Network. Benefits and harms, patient values and preferences, resources, equity, acceptability and feasibility all informed the recommendations. Cost-effectiveness data were considered when available, though no formal economic analysis was performed for this update.
That structure matters because osteoporosis care is delivered mainly outside specialty clinics. Primary care clinicians need a framework that is evidence-based but workable: who to screen, when to treat, how to individualize therapy, and when to reconsider the plan. The guideline answers those questions with 25 recommendations and 10 good practice statements.
The clinical target is older adults who can still benefit from prevention before the first major fracture occurs. If the guideline succeeds in everyday practice, it will do so by making fracture risk assessment more consistent, by reducing missed vertebral fractures, and by narrowing the gap between what is known about osteoporosis and what actually happens in primary care.